Communiqués ImmunityBio, Inc.

Actions

IBRX

US45256X1037

Temps réel estimé Cboe BZX Autres places de cotation 16:52:02 03/06/2024			Varia. 5j.	Varia. 1 janv.
6,35 ^USD	-1,09 %		-6,95 %	+22,71 %

09/05	ImmunityBio, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
07/05	Les actions d'ImmunityBio augmentent après l'achèvement de la fabrication de la substance médicamenteuse pour le traitement du cancer	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

ImmunityBio - Connecting the Dots of ANKTIVA's Triangle Offense, A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast	20/05	AQ
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast	17/05	BU
ImmunityBio: Q1 Earnings Snapshot	10/05	AQ
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	07/05	BU
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types	02/05	BU
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA Approval in Fireside Chat at the Annual Conference of the American Urological Association	01/05	AQ
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association	30/04	BU
ImmunityBio : Investor Live Audio Webcast – ANKTIVA Post Approval	27/04	PU
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer	26/04	AQ
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer	25/04	BU
ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	23/04	AQ
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	23/04	BU
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy	06/03	BU
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study	05/03	BU
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	21/02	BU
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG	05/02	BU
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million	02/01	BU
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference	16/11	BU
ImmunityBio: Q3 Earnings Snapshot	09/11	AQ
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity	07/11	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués ImmunityBio, Inc.

Actions

IBRX

US45256X1037

Communiqués

Filtres